Viridian Therapeutics is a biopharmaceutical company developing medicines for serious and rare diseases, with a focus on thyroid eye disease. VRDN reports earnings on Wed, Nov 4, 2026. In the past 30 days there were 2 dark pool prints.
Earnings
Earnings calendar →Analyst Ratings & Price Targets
Analyst Ratings →| Date | Firm | Action | Rating | Price target |
|---|---|---|---|---|
| Sep 22 | RBC Capital | Target raised | Buy | |
| Aug 7 | RBC Capital | Target raised | Buy | |
| Aug 7 | Truist Securities | Target raised | Buy | |
| Jun 30 | RBC Capital | Maintained | Buy | |
| Jun 30 | Truist Securities | Maintained | Buy |
Whale Options Flow
90DNo whale options trades in VRDN in the last 90 days.
Dark Pool
30DAI Auto Pilots
Paper tradingStreetAlpha runs four autonomous AI traders powered by Anthropic's Claude. Each one reads options flow, dark pool prints, insider filings, sentiment, macro signals and technicals, then makes its own trading decisions in a paper portfolio. Every decision is logged and every trade is tracked, so you can see whether VRDN is in one of them and how their past VRDN trades turned out.
Macro & Market News
All StreetAlpha news →StreetAlpha hasn't covered VRDN in an article yet. Here's the latest on the wider market.
About Viridian Therapeutics
Viridian Therapeutics is a biopharmaceutical company based in Waltham, Massachusetts. It develops medicines for serious and rare diseases, with its main focus on thyroid eye disease, a rare autoimmune condition that affects the eyes. Its pipeline includes antibody treatments that target the IGF-1R pathway and engineered FcRn inhibitors being studied for several autoimmune disorders. The company is preparing to sell its medicines to patients, physicians and insurers if they are approved.
- Headquarters
- Waltham, MA